These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
427 related articles for article (PubMed ID: 8247275)
1. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP? Herrero MT; Hirsch EC; Kastner A; Ruberg M; Luquin MR; Laguna J; Javoy-Agid F; Obeso JA; Agid Y Neuroscience; 1993 Sep; 56(2):499-511. PubMed ID: 8247275 [TBL] [Abstract][Full Text] [Related]
2. GM-1 ganglioside promotes the recovery of surviving midbrain dopaminergic neurons in MPTP-treated monkeys. Herrero MT; Perez-Otaño I; Oset C; Kastner A; Hirsch EC; Agid Y; Luquin MR; Obeso JA; Del Rio J Neuroscience; 1993 Oct; 56(4):965-72. PubMed ID: 7904332 [TBL] [Abstract][Full Text] [Related]
3. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonian syndrome in Macaca fascicularis: which midbrain dopaminergic neurons are lost? German DC; Dubach M; Askari S; Speciale SG; Bowden DM Neuroscience; 1988 Jan; 24(1):161-74. PubMed ID: 3259295 [TBL] [Abstract][Full Text] [Related]
4. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. German DC; Manaye KF; Sonsalla PK; Brooks BA Ann N Y Acad Sci; 1992 May; 648():42-62. PubMed ID: 1353337 [TBL] [Abstract][Full Text] [Related]
5. Selective retention of MPP+ within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Herkenham M; Little MD; Bankiewicz K; Yang SC; Markey SP; Johannessen JN Neuroscience; 1991; 40(1):133-58. PubMed ID: 2052148 [TBL] [Abstract][Full Text] [Related]
6. Selective loss of subpopulations of ventral mesencephalic dopaminergic neurons in the monkey following exposure to MPTP. Schneider JS; Yuwiler A; Markham CH Brain Res; 1987 May; 411(1):144-50. PubMed ID: 2886180 [TBL] [Abstract][Full Text] [Related]
7. Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Varastet M; Riche D; Maziere M; Hantraye P Neuroscience; 1994 Nov; 63(1):47-56. PubMed ID: 7898660 [TBL] [Abstract][Full Text] [Related]
8. Reduced noradrenergic innervation of ventral midbrain dopaminergic cell groups and the subthalamic nucleus in MPTP-treated parkinsonian monkeys. Masilamoni GJ; Groover O; Smith Y Neurobiol Dis; 2017 Apr; 100():9-18. PubMed ID: 28042095 [TBL] [Abstract][Full Text] [Related]
9. Decreased tyrosine hydroxylase content in the dopaminergic neurons of MPTP-intoxicated monkeys: effect of levodopa and GM1 ganglioside therapy. Kastner A; Herrero MT; Hirsch EC; Guillen J; Luquin MR; Javoy-Agid F; Obeso JA; Agid Y Ann Neurol; 1994 Aug; 36(2):206-14. PubMed ID: 7914399 [TBL] [Abstract][Full Text] [Related]
10. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Hirsch E; Graybiel AM; Agid YA Nature; 1988 Jul; 334(6180):345-8. PubMed ID: 2899295 [TBL] [Abstract][Full Text] [Related]
11. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity. D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568 [TBL] [Abstract][Full Text] [Related]
12. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? Kastner A; Hirsch EC; Lejeune O; Javoy-Agid F; Rascol O; Agid Y J Neurochem; 1992 Sep; 59(3):1080-9. PubMed ID: 1494900 [TBL] [Abstract][Full Text] [Related]
13. MPTP-induced ventral mesencephalic cell loss in the cat. Williams JL; Schneider JS Neurosci Lett; 1989 Jul; 101(3):258-62. PubMed ID: 2570385 [TBL] [Abstract][Full Text] [Related]
14. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. German DC; Nelson EL; Liang CL; Speciale SG; Sinton CM; Sonsalla PK Neurodegeneration; 1996 Dec; 5(4):299-312. PubMed ID: 9117541 [TBL] [Abstract][Full Text] [Related]
15. Chronic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to monkeys: behavioural, morphological and biochemical correlates. Albanese A; Granata R; Gregori B; Piccardi MP; Colosimo C; Tonali P Neuroscience; 1993 Aug; 55(3):823-32. PubMed ID: 8105418 [TBL] [Abstract][Full Text] [Related]
16. Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Masilamoni GJ; Bogenpohl JW; Alagille D; Delevich K; Tamagnan G; Votaw JR; Wichmann T; Smith Y Brain; 2011 Jul; 134(Pt 7):2057-73. PubMed ID: 21705423 [TBL] [Abstract][Full Text] [Related]
17. Neuromelanin accumulation with age in catecholaminergic neurons from Macaca fascicularis brainstem. Herrero MT; Hirsch EC; Kastner A; Luquin MR; Javoy-Agid F; Gonzalo LM; Obeso JA; Agid Y Dev Neurosci; 1993; 15(1):37-48. PubMed ID: 7505739 [TBL] [Abstract][Full Text] [Related]
18. Dopaminergic neurons expressing calbindin in normal and parkinsonian monkeys. Lavoie B; Parent A Neuroreport; 1991 Oct; 2(10):601-4. PubMed ID: 1684519 [TBL] [Abstract][Full Text] [Related]
19. Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques. Bensaid M; Tandé D; Fabre V; Michel PP; Hirsch EC; François C Eur J Neurosci; 2015 Jan; 41(1):129-36. PubMed ID: 25328140 [TBL] [Abstract][Full Text] [Related]
20. Pharmacological inactivation of the vesicular monoamine transporter can enhance 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration of midbrain dopaminergic neurons, but not locus coeruleus noradrenergic neurons. German DC; Liang CL; Manaye KF; Lane K; Sonsalla PK Neuroscience; 2000; 101(4):1063-9. PubMed ID: 11113355 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]